Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT06031454
- Locations
- 🇨🇳
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06024915
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
TB YOUTH - TB SYstemic Management Using One-month, Ultra-short TPT Regimen for ScHool Contacts
- Conditions
- TuberculosisLatent Tuberculosis
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 2978
- Registration Number
- NCT06022146
- Locations
- 🇨🇳
People's Hospital of Fenggang, Zunyi, Guizhou, China
🇨🇳People's Hospital of Honghuagang District, Zunyi, Guizhou, China
🇨🇳People's Hospital of Meitan, Zunyi, Guizhou, China
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT06004947
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM
- Conditions
- Comorbidities and Coexisting ConditionsSevere Acute MalnutritionChild MalnutritionHIV
- Interventions
- Other: Standard CareBehavioral: The Friendship BenchDietary Supplement: Reformulated Ready to Use Therapeutic FoodBehavioral: Care for Child DevelopmentBehavioral: Educational and behaviour-change modules
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 1266
- Registration Number
- NCT05994742
- Locations
- 🇿🇲
Matero Hospital, Lusaka, Zambia
🇿🇲UTH - University Teaching Hospital, Lusaka, Zambia
🇿🇼Chitungwiza Central Hospital, Harare, Zimbabwe
Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05991401
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Intensified Short Course Regimen for TBM in Adults
- Conditions
- Tuberculous Meningitis
- Interventions
- Drug: High dose rifampicin (25mg/kg)Drug: HRZEDrug: HREDrug: Steroid
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Indian Council of Medical Research
- Target Recruit Count
- 372
- Registration Number
- NCT05917340
- Locations
- 🇮🇳
ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India
Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 20
- Registration Number
- NCT05902728
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 42
- Registration Number
- NCT05899829
- Locations
- 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Drug: Rifafour e-275Drug: Amoxicillin/CA twice dailyDrug: Amoxicillin/CA once daily
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 134
- Registration Number
- NCT05896930
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.